Oral Semaglutide Brand Name
The oral formulation of semaglutide is marketed under the brand name Rybelsus®. 1, 2, 3, 4
Key Distinguishing Features
Rybelsus® represents the first orally administered GLP-1 receptor agonist approved for clinical use, distinguishing it from the injectable semaglutide formulations marketed as Ozempic® (for type 2 diabetes) and Wegovy® (for obesity management). 1, 5, 4
Formulation Technology
- Rybelsus® is co-formulated with the absorption enhancer sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC), which facilitates peptide absorption across the gastric epithelium despite the acidic stomach environment. 1, 2, 4
Available Dosing
- Rybelsus® is available in three tablet strengths: 3 mg, 7 mg, and 14 mg, designed for gradual dose escalation. 2, 4
FDA-Approved Indication
- Rybelsus® is indicated exclusively for type 2 diabetes management as an adjunct to diet and exercise, either as monotherapy (in metformin-intolerant patients) or in combination with other glucose-lowering agents including insulin. 1, 3
Critical Administration Requirements
- Rybelsus® must be taken on an empty stomach with ≤120 mL water, with a mandatory 30-minute wait before eating or taking other medications to ensure adequate absorption. 6
Important Clinical Distinction
Rybelsus® is NOT approved for obesity management without diabetes, unlike the injectable semaglutide 2.4 mg formulation (Wegovy®). 7, 5 Oral semaglutide demonstrates lower potency for weight loss compared to injectable formulations, achieving HbA1c reductions of approximately 1.4% but modest weight loss. 6, 7